World Child Cancer is delighted to announce the expansion of a pilot project with Sandoz, a global leader in generic pharmaceuticals and biosimilars. The project aims to improve access to treatment and optimize survival outcomes for children suffering from cancer in four low and middle income countries.
Jon Rosser, Chief Executive of World Child Cancer, said: “It is just unacceptable that children’s odds of surviving cancer depend so much on geography. In high income countries, 80% now survive, but in low and middle income countries it’s still only about 10%. World Child Cancer is changing this – in our programmes we can raise that survival rate to around 60%.”
He added: “We are very excited at this growing partnership with Sandoz, which will enable us to prevent so many children dying without even a diagnosis and without effective pain relief. We believe that all children, regardless of where they live, deserve better.”
The agreement builds on an existing partnership with Sandoz in the Philippines, where Sandoz is funding essential healthcare staff training needs and helping children to access diagnosis and subsequent treatment. It expands the partnership to cover three additional countries across three continents: Ghana, Mexico and Myanmar.
These particular projects were chosen because of the gravity of the situation in the four regions concerned: across all four, an estimated 6000 children develop cancer each year, but approximately only 20% even receive a diagnosis, let alone effective treatment.
Peter Stenico, Sandoz Head of Oncology, said: “These projects will take simple, pragmatic measures to attack cancer where it is most vulnerable: among underprivileged children suffering from forms of cancer that are absolutely treatable. Together with World Child Cancer, we believe we can make a real difference by enhancing the standard of care for children in these countries and, ultimately, improving childhood cancer survival rates.”
The expanded partnership highlights World Child Cancer’s commitment to improve diagnosis, treatment and support for children with cancer, and their families, in the low and middle income world.